Formulation and Evaluation of Orally Disintegrating Tablets of Rosuvastatin

Rosuvastatin is a Dyslipidaemic Agents, which acts by inhibition of HMG-CoA reductase enzyme. Used in the treatment of hyperlipidemia. Therefore the present investigation was to design a formulation of orally disintegrating tablets of Rosuvastatin. Orally disintegrating tablets of Rosuvastatin were formulated by Superdisintegrant addition method by direct compression technique. All the fourteen formulations were evaluated for disintegration time, hardness and friability, this Superdisintegrant addition method exhibits the lowest disintegration time, hence it is ranked as the best among the methods. Further fourteen batches were prepared by using sodium starch glycolate, croscaramellose sodium, Lycoat Rs720 and cross povidone in different concentrations. All the formulations were evaluated for weight variation, hardness, friability, drug content, invitro disintegration time, wetting time, in-vitro dissolution study. Among all the formulations F13 (containing crosspovidone and sodium starch glycolate (1:1) (8%)) was considered to be the best formulation, which release up to 97% of the drug in 5 mins. A comparison of In vitro drug release was made with marketed product of Rosuvastatin which shows 93% drug release in 1 hour. From this study we can made the conclusion that formulated tablets of Rosuvastatin containing crosspovidone and sodium starch glycolate are better and effective than conventional tablets to meet patient compliance.